Longer, Faster Blood Cleaning Treatment for People on Hemodialysis
Tests a longer, faster blood cleaning treatment in adults on hemodialysis.
Plain-language title generated from the registry record
Registry title: Long-term, High Blood Flow Hemoadsorption Therapy in Patients Undergoing Maintenance Hemodialysis
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with kidney failure who already have regular maintenance hemodialysis together with hemoadsorption. It tests a longer, higher blood flow hemoadsorption session.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Kidney failure (uremia) treated with regular maintenance hemodialysis and hemoadsorption
- Earlier treatment
- Must already receive regular hemoadsorption plus hemodialysis treatment
Main reasons for not taking part
- Plasma albumin below 30g/L, severe malnutrition or cachexia
- Platelet count below 40×10^9/L or above 300×10^9/L
- Blood clots too easily (hypercoagulable state) or allergy to the hemoperfusion device
- Poor vascular access, so blood flow cannot reach 250ml/min
- Use of anticoagulants other than heparin
This trial only enrols participants on dialysis. The registry sentence this rests on: Maintenance Hemodialysis Patients with Uremia receive regular HA+HD treatment
Read by machine on 9 November 2026.
Where in China
- Nephrology Department of Beijing Jishuitan HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Dongliang Zhang, MD
- Trial code
- NCT06574425
- Record updated
- 18 December 2024
- Original description
Objective：The purpose of the study is to confirm that extending the duration of hemoadsorption (HA) and increasing blood flow during the HA+hemodialysis (HD) treatment process is safe and feasible, and to verify that extending the HP treatment duration can further increase the clearance of protein-bound uremic toxins.Read full original descriptionShow less
A Multicenter, Prospective, Cohort Study on the Safety and Efficacy of Long-term, High Blood Flow Hemoadsorption Therapy in Patients Undergoing Maintenance Hemodialysis
Objective：The purpose of the study is to confirm that extending the duration of hemoadsorption (HA) and increasing blood flow during the HA+hemodialysis (HD) treatment process is safe and feasible, and to verify that extending the HP treatment duration can further increase the clearance of protein-bound uremic toxins.
Methods: The study employs a multicenter, prospective, cohort design with a self-controlled before-and-after comparison. The duration of HA+HD treatment for maintenance hemodialysis (MHD) patients is extended to 4 hours, and the extracorporeal blood flow rate is increased to over 250-350 ml/min. The safety of the treatment is assessed by evaluating the safety of the procedure; the levels of relevant toxins in the patients' blood are measured before and after treatment, and the clearance rate of uremic toxins after a single treatment is calculated and compared with the self-controlled before-and-after data to determine whether the modified protocol can remove more uremic toxins.
Inclusion: Maintenance Hemodialysis Patients with Uremia receive regular HA+HD treatment.
Exclusion: Plasma albumin <30g/L, severe malnutrition or cachectic state; platelet count <40×10\^9/L or >300×10\^9/L; hypercoagulable state allergy to the hemoperfusion device; new cardiovascular or cerebrovascular diseases; poor vascular access function, extracorporeal circulation blood flow unable to reach 250ml/min ultrafiltration volume >4500ml in a single dialysis session use of non-heparin anticoagulants inability to comply with the procedures of this study other conditions deemed unsuitable for participation in this study by the investigator; -.